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ABSTRACT 
POLYCHLORINATED BIPHENYL 153 EXACERBATES NONALCOHOLIC 
FATTY LIVER DISEASE IN C57BU6 MICE 
Banrida Wahlang 
April 04,2012 
Polychlorinated biphenyls (PCBs) are persistent environmental pollutants which 
are detectable in the serum of all American adults. Amongst PCB congeners, 
PCB 153 has the highest serum level. PCBs have been dose-dependently 
associated with suspected nonalcoholic fatty liver disease (NAFLD), obesity and 
metabolic syndrome in epidemiological studies. The purpose of this study is to 
determine if PCB 153 induces NAFLD in mice fed a control diet (CD), and 
exacerbates NAFLD in mice fed a high fat diet (HFD). C57BL6/J mice were fed 
either control or 42% milk fat diet for 12 weeks with or without PCB 153 co-
exposure (50 mg/kg i.p. x 4). Glucose tolerance tests were performed, and 
plasma/tissues were obtained at necropsy for measurements of adipocytokine 
levels, histology, and gene expression microarrays. In mice fed CD, the addition 
of PCB 153 had little to no effect on any of the measured parameters. In contrast, 
PCB 153 co-exposure in high fat-fed mice was associated with dramatically 
increased visceral adiposity, hepatic steatosis and increased plasma adipokines 
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including adiponectin, leptin, resistin and plasminogen activator inhibitor-1 levels. 
Likewise, co-exposure reduced expression of hepatic genes implicated in ~­
oxidation while increasing the expression of genes associated with lipid 
biosynthesis. Regardless of diet, PCB 153 had no effect on insulin resistance or 
tumor necrosis factor alpha levels. However, HFD+PCB 153 appeared to induce 
an endoplasmic reticulum (ER) stress response. Therefore, PCB 153 is an 
obesogen which exacerbates hepatic steatosis; alters adipocytokines; and 
disrupts normal hepatic lipid metabolism when administered with HFD. Because 
all U.S. adults have been exposed to PCB 153, this particular nutrient-toxicant 
interaction potentially impacts on the progression of human NAFLD. 
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Polychlorinated biphenyls (PCBs) 
Polychlorinated biphenyls (PCBs) are halogenated compounds consisting 
of up to 10 chlorine atoms attached to a biphenyl group. They were 
manufactured during 1930s-1970s and were used as dielectric and heat transfer 
fluids in electric transformers, wax extenders, flame retardants and as a source 
of chlorine content. A total of 1.3 million tons of PCBs containing about 130 
congeners was manufactured worldwide prior to their banning in 1977 (1). 
Monsanto, a well-known PCB manufacturer in North America, produced PCB 
mixtures under the brand name Aroclor at several plants including Anniston, 
Alabama. High-level environmental contamination during production resulted in 
increased PCB body burden in Anniston residents (2). Although PCBs have been 
banned for over 30 years, their high thermodynamic stability make them resistant 
to chemical degradation in the environment and hence, PCBs, belong to the 
category of 'persistent organic pollutants' (POPs). PCBs are still present in our 
ecosystem, including the atmospheric air, lakes, rivers, fish, human adipose 
tissue, serum and breast milk. Humans are exposed to PCBs through inhalation 
of PCB-contaminated air or ingestion of PCB-contaminated food. In fact, PCBs 
continue to be present in the food supply and daily intake in the American diet is 
estimated to be approximately 30 ng/day based on a recent study from a Dallas 
supermarket (3). PCBs are the 5th most hazardous substances on the CERCLA 
priority list (2007). The National Health and Nutrition Examination Study 
(NHANES) indicates that 100% of adult NHANES participants had detectable 
circulating PCB levels and PCB 153 (2,2',4,4',5,5'-hexachlorobiphenyl) has the 
highest median serum concentration in humans amongst all PCB congeners (5). 
Non-alcoholic fatty liver disease (NAFLO) 
A previous study from our laboratory group identified suspected non-
alcoholic fatty liver disease (NAFLD) and toxicant associated steatohepatitis 
(TASH) in the NHANES participants with chronic low-level environmental 
exposures to POPs including PCBs (4). NAFLD represents a pathological 
spectrum of diseases ranging from lipid accumulation in the hepatocytes 
(steatosis) to the development of superimposed inflammation (steatohepatitis) 
and ultimately fibrosis and cirrhosis. NAFLD is the most prevalent liver disease in 
North America. It resembles alcoholic fatty liver disease although it occurs in 
non-alcoholic subjects. The pathogenesis of NAFLD has been reviewed (5), and 
key mechanisms include altered adipo-cytokines with low adiponectin and high 
leptin levels (5, 6) and production of pro-inflammatory cytokines such as TNFa 
and IL-6 (7). NAFLD gives rise to hepatic insulin resistance and systemic 
inflammation, which in turn, induces obesity, diabetes and the metabolic 
syndrome (8, 9). Moreover, NAFLD is also exacerbated by diabetes (10) and is 
associated with obesity (5). Because it is often seen in association with insulin 
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resistance and dyslipidemia, NAFLD is generally regarded to be the hepatic 
manifestation of obesity and the metabolic syndrome. Interestingly, inflamed and 
fatty liver conditions are not confined to obese individuals only, but other factors 
can predispose a person to steatohepatitis. Therefore, it is possible that primary 
factors such as consumption of hyper-caloric foods can lead to steatosis in 
normal individuals but secondary factors such as POPs can act as a second hit 
and worsen this effect, leading to a diseased state. 
Effects of PCB exposure in humans 
Our laboratory group recently identified advanced steatohepatitis 
associated with insulin resistance and increased pro-inflammatory cytokines in 
non-obese chemical workers who were subjected to high-level industrial 
chemical exposures. The term TASH was then coined to describe this condition 
(11). Our initial work was focused on TASH in non-obese vinyl chloride workers; 
in our recent work however, our laboratory group identified suspected 
NAFLDITASH in NHANES participants with low-level environmental exposures to 
POPs including PCBs (4, 11). Other epidemiologic studies have found 
associations between PCBs and metabolic disorders associated with NAFLD 
including obesity (12, 13), insulin resistance/diabetes (14-16), and the metabolic 
syndrome (13,17). Furthermore, follow-up of subjects involved in the "Yu-cheng" 
incident in Taiwan, one of the two known major human PCB intoxication 
episodes, where cooking oil had been highly contaminated by PCBs, the 
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mortality rate due to cirrhosis was 2.7 -fold higher than expected (18), although 
pathologic confirmation was not provided. 
Structure-activity and toxicity relationship 
The PCB's structure determines the compound's activity and toxicity. 
Based on the chlorine substitution in the two phenyl rings, PCBs can be 
classified as either planar or non co-planar (Figure 1). Planar PCBs have chlorine 
substitutions in either the meta- or para- positions but not in the ortho- positions. 
Non co-planar PCBs have ortho- substituted chlorine atoms, apart from meta-
and/or para- substitutions. PCB studies focused on hepatocarcinogenesis and 
receptor-based mechanisms including the aryl hydrocarbon receptor (AhR) 
(coplanar or dioxin-like PCBs), the constitutive androstane receptor (CAR) (non-
coplanar or non-dioxin-like PCBs), and more recently, the estrogen receptor (19-
21). The AhR is a member of the PAS domain protein family of transcription 
factors and regulates a battery of genes involved with xenobiotic detoxification 
including CYP1 A and CYP1 B which can, in turn, bio-transform or activate pro-
carcinogens to their carcinogenic forms. Depending on the type of PCB-receptor 
interaction, PCBs have a tendency to induce pro-carcinogens leading to 
carcinogenicity or they can cause hepatomegaly and fatty liver. Coplanar PCBs 
such as PCB 126 are AhR agonists similar to dioxin (22). Previous work has 
implicated dioxins and dioxin-like PCBs in animal models of steatohepatitis (23, 
24). However, by mass, dioxin-like PCBs are a relatively minor component of the 
total PCB burden in human serum (4). Moreover, PCBs do not appear to be as 
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carcinogenic in man as they are in rodents (eg: PCB 126), and this may be due 
to differences in the AhR structure and in the battery of target genes between 
species (25). From a mechanistic standpoint, a PCB's structure determines its 
ability to interact with nuclear receptors as well. A theoretical structure-activity 
relationship study predicted that ortho-substituted PCBs can interact with the 
pregnane-X-receptor (PXR), estrogen receptor(ER), androgen receptor (AR) and 
thyroid receptor (TR) (26). PCB 153, an ortha-substituted, non co-planar PCB 
(Figure 1) has been studied extensively by the National Toxicology Program 
(NTP) in female Harlan Sprague-Dawley (SO) rats and the mode of action has 
been attributed to the compound's interaction with CAR (27-29). The studies also 
demonstrated PCB-induced hepatotoxicity (20, 27). Furthermore, nutrient-
toxicant interactions appear to be important in diet-induced obesity/metabolic 
syndrome (30) and NAFLD (5). However, the effect of PCB 153, a lipid soluble, 
non-dioxin like PCB which concentrates in adipose tissue has not been 
adequately studied in animal models of NAFLD. 
PCB's metabolism is defined by the number of chlorine atoms present. 
Low molecular weight PCBs (mono-, di-, tri- or tetra-chlorinated) are hydroxylated 
by cytochrome P450 enzymes (31). The metabolized PCBs, also known as 
biotransformed congeners, can form DNA adducts or bind to proteins to exert 
their toxic effects. High molecular weight PCBs, on the other hand, do not 
metabolize, hence they are known as persistent congeners. These PCBs such as 
the hexa-chlorinated PCB 153, bioaccumulate in the adipose tissue (32). 
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Figure 1. Chemical structure of PCBs. 
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Significance of the study 
Obesity has been identified as a leading "preventable cause of death" by 
the World Health Organization (WHO), and many health authorities view it as one 
of the most serious health problems of the 21 st century (25). The annual cost of 
obesity treatment in the US alone was recently estimated at $147 billion (1). 
According to the data from NHANES 2007-2008,33.8% of US adults are obese 
(defined by body mass index, BMI ~ 30) with another 34.2% being overweight 
(defined by BMI ~ 25) (26). Alarmingly, obesity is not restricted to the adult 
population; 15% of children and adolescents in the US are obese (27). 
Overweight/obesity is one of the defining features of metabolic syndrome, 
a metabolic disorder which is also characterized by insulin resistance, 
hypertension, and dyslipidemia (28). The prevalence of metabolic syndrome in 
US adults was recently estimated at 34.3% (29). The obesity epidemic is strongly 
associated with increased type 2 diabetes which is the late stage of insulin 
resistance. The National Diabetes Fact Sheet obtained from the Center for 
Disease Control and Prevention (CDC, 2011) reports that 25.8 million Americans 
have diabetes with another 79 million being insulin resistant. Obesity, insulin 
resistance, and metabolic syndrome eventually lead to target organ damage 
including fatty liver disease, cardiovascular disease, chronic kidney disease, and 
cancer. 
The pathogenesis of obesity, insulin resistance, and the metabolic 
syndrome is complex. Historically, obesity was blamed on over-nutrition and 
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genetic background. However, recent literature reports implicated NAFLD (2, 
30,31) and persistent organic pollutants such as PCBs (3-10,12-15,32) as 
key players in the development of obesity and the metabolic syndrome. 
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CHAPTER 2 
PCB 153 WORSENS DIET INDUCED OBESITY IN C57BU6 MICE 
INTRODUCTION 
Epidemiologic studies have implicated PCBs in metabolic disorders 
associated with NAFLD including obesity (12, 13), insulin resistance/diabetes 
(14-16), and the metabolic syndrome (13,17). Moreover, PCB 153 had the 
highest median serum levels in NHANES participants, than any single PCB 
congener. It therefore becomes crucial to evaluate the role of PCB 153 in 
induction of obesity or worsening diet-induced obesity. 
In this study, PCB 153 is hypothesized to act as a relevant "second hit" 
mechanism in the genesis and progression of NAFLD occurring in the context of 
a high fat diet. The first purpose of this study is to determine, if PCB 153 alone is 
capable of inducing NAFLD in mice fed a control diet (normal chow diet). The 
second purpose of the study is to determine if PCB exposures increase NAFLD 
occurring on a background of diet-induced obesity by worsening previously 
implicated mechanisms such as insulin resistance. 
C57BL6/J mice were used in our 12 week study. The mice were fed either 
control diet or 42% milk fat diet with or without PCB 153 co-exposure (50 mg/kg 
i.p. x 4). NAFLD is characterized by hepatic steatosis, inflammation and 
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dysregulation in adipokine levels. The objective of our study is to validate if the 
PCB 153-exposed animals gain weight, showed steatosis, insulin resistance or 
any other form of metabolic disorder. 
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MATERIALS AND METHODS 
Animals and diets. The animal protocol was approved by the University of 
Louisville Institutional Animal Care and Use Committee. Male C57BU6J mice (8 
weeks old, n=40; The Jackson Laboratory, Bar Harbor, Maine) were divided into 
4 study groups (n=10) based on diet and PCB 153 exposure in this 12 week 
study utilizing a 2x2 design. Mice were fed either a high fat diet (HFD, 42% kCal 
from fat; TD.88137 Harlan Teklad) or a control diet (CD, 13.5% kCal from fat; 
5010 LabDiet). Diet composition is shown in Table 1. PCB 153 (Ultra Scientific, 
North Kingstown, RI), was administered in corn oil (vehicle) by IP injection (vs. 
corn oil alone) at a dose of 50 mg/kg on weeks 4, 6, 8, and 10 (200mg/kg of PCB 
153 cumulative). This dose was chosen based on previous NTP TR 530 study 
(3000 Ilg/kg by gavage, 5 days per week for 14 weeks:::: 210 mg/kg of PCB 153 
cumulative) (28). Mice were housed in a temperature-and light-controlled room 
(12h light; 12h dark) with food and water ad libitum. Glucose tolerance tests were 
performed at week 11, and the animals were euthanized (sodium pentobarbital, 
40 mg/kg body weight, i.p.) at the end of week 12. Thus four different treatment 
groups were evaluated in this fashion: CD, CD+PCB 153, HFD, HFD+PCB. 
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Control Diet High Fat Diet 
%kCal Source %kCal Source 
Protein 28.5 Soybean Meal 15.2 Casein 
Sucrose/Corn 
Carbohydrate 58.0 Starch/Sucrose 42.7 
starch 
Fat 13.5 Ether extract 42 Milk Fat 
Table 1. Diet composition. 
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Glucose tolerance test. The glucose tolerance test (GTT) was performed 2 
weeks prior to the end of study. On the day of test, mice were fasted for 6 h (9 
A.M.-3 P.M.) and fasting blood glucose level was measured with a hand-held 
glucometer (ACCU-CHEK Aviva, Roche, Basel, Switzerland) using 1 III blood via 
tail snip. Glucose was then administered (1 mg glucose/g body weight, sterile 
saline, i.p.), and blood glucose was measured at 5, 15,30,60,90 and 120 min 
post-injection. Insulin resistance was calculated by homeostasis model 
assessment (HOMA) using the formula HOMA-IR = Fasting glucose (mg/dL) x 
Fasting insulin (~U/mL) /405 (20). 
Liver histological studies. Liver sections were frozen using optimal cutting 
temperature (OCT), a liquid embedding medium, or fixed in 10% buffered 
formalin for 24 h and embedded in paraffin for histological examinations. Tissue 
sections were stained with either Oil Red a (frozen OCT), hematoxylin-eosin 
(H&E; formalin-fixed) or Sirius red stain (formalin-fixed) and examined under light 
microscopy at 200X magnification. Photomicrographs were captured using a 
Nikon Eclipse E600 Microscope. 
Liver enzymes, lipids and TNFa mRNA measurements. Plasma aspartate 
transaminase (AST), alanine transaminase (AL T), cholesterol, triglyceride, high 
density lipoprotein (HDL) and low density lipoprotein (LDL) levels were measured 
using Cobas Mira Plus automated chemical analyzer (Roche, Basel, 
Switzerland). Real-time polymerase chain reaction (RT -PCR) experiments were 
used to measure hepatic tumor necrosis factor alpha (TN Fa) mRNA. Animal liver 
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was homogenized and total RNA was extracted using the RNA-STAT 60 protocol 
(Tel-Test, Austin, TX). cDNA was synthesized from total RNA using the 
QuantiTect Reverse Transcription Kit (Qiagen, Valencia, CA). PCR was 
performed on the Applied Biosystems StepOnePlus Real-Time PCR Systems 
using the Taqman Universal PCR Master Mix (Life Technologies, Carlsbad, CA). 
Primer sequence for TNFa (Mm00443258-m1) was obtained from Taqman Gene 
Expression Assays (Applied Biosystems, Foster City, CA). The levels of mRNA 
were normalized relative to the amount of glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) (4352932E). Expression levels in mice fed CD and 
administered vehicle were set at 100%. Gene expression levels were calculated 
according to the 2-MCt method (33). 
Measurement of hepatic triglyceride and cholesterol content. Frozen mouse 
livers were washed in neutral 1 X phosphate buffered saline and pulverized. 
Hepatic lipids were extracted by an aqueous solution of chloroform and 
methanol, according to the Bligh and Dyer method (21), dried using nitrogen and 
re-suspended in 5% lipid free bovine serum albumin. Triglycerides and 
cholesterol were quantified using the Cobas Mira Plus automated chemical 
analyzer. The reagents employed for the assay were L-Type Triglyceride M 
(Wako Diagnostics, Richmond, VA) and Infinity Cholesterol Liquid Stable 
Reagent (Fisher Diagnostics, Middletown, VA) for triglycerides and cholesterol 
respectively. 
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Statistical Analysis. Statistical analyses were performed using GraphPad Prism 
version 5.01 for Windows and SigmaPlot 11.01. Data are expressed as mean ± 
SEM. For 2 group comparison, an unpaired t-test was used, and multiple group 
data were compared using Two Way ANOVA followed by Tukey Test for post-
hoc all pairwise comparisons. P <0.05 was considered statistically significant. 
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RESULTS 
PCB 153 treatment increased body weight and visceral adiposity in mice 
fed high fat diet, but had no effect in mice fed control diet. 
During the 12 week experiment, all groups experienced weight gain 
(Figure 2). PCB 153 administration had no significant effect on mean percent 
body weight gain in mice fed CD (111.10 ± 0.75% for CD VS. 107.50 ± 1.73% for 
CD+PCB 153). In contrast, PCB 153 significantly increased body weight gain in 
mice fed with HFD (122.80 ± 1.98%) VS. HFD+vehicle (114.40 ± 2.56%, P <0.05). 
There was a significant interaction between HFD and PCB 153 using Two Way 
ANOVA (p =0.002). 
On H&E stain, epididymal adipocyte size was increased by HFD, but PCB 
153 had no additive effect (Figure 3). In mice fed with CD, the mean epididymal 
adipocyte area (~m2) was 1357.95 ± 70.73 ~m2 with vehicle control and this was 
significantly increased with PCB 153 (1806.46 ± 169.46 ~m2, p=0.02) (Figure 4). 
In mice fed HFD, adipocyte size was not significantly different for vehicle 
(5643.82 ± 632.49 ~m2) VS. PCB 153 (5371.29 ± 484.91 ~m2). However, 
adipocyte size was significantly larger with HFD+vehicle VS. both CD+vehicle and 
CD+PCB 153 (p <0.05). Likewise, mean adipocyte size was larger with 
HFD+PCB 153 VS. both CD+vehicie and CD+PCB 153 (p <0.05). Therefore, PCB 
153 increased diet-induced obesity, independent of effects on adipocyte size. 













Figure 2. PCB 153 increased body weight and visceral adiposity in mice fed 
HFD. 
The % increase in body weight for C57BU6J mice (n=10) treated with a 42% milk 
fat diet (vs. CD) ± PCB 153 (200 mg/kg cumulative) . Body weight measurements 
were taken from week 1 to week 12 (12 weeks) and the body weight at week 1 
was taken as 100%. Data are expressed as mean ± SEM. * P <0.05. CD-control 
diet, HFD-high fat diet, PCB-polychlorinated biphenyl. 
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CD CD+PCB 153 
HFD HFD+PCB 153 
Figure 3. H&E staining showed HFD increased adipocyte cell size and this 
was unaffected by PCB 153. 
Epipdidymal adipose tissue was stained with H&E and images were captured 
using a Nikon Eclipse E600 Microscope. The adipocyte cell size was increased in 
mice fed with HFD and th is effect was not changed with PCB 153 co-
administration. CD-control diet, HFD-high fat diet, PCB-polychlorinated biphenyl. 
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Figure 4. HFD increased adipocyte cell size <.,..m2) and this was unaffected 
by PCB 153. 
Adipocyte area was measured and the average cell size of > 100 cells for each of 
the groups (n=1 0) was calculated. The adipocyte cell size (11m2) was increased in 
mice fed with HFD and th is effect was not changed with PCB 153 co-
administration. Data are expressed as mean ± SEM. * P <0.05. CD-control diet, 
HFD-high fat diet, PCB-polychlorinated biphenyl. 
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PCB 153 worsened NAFLD in mice fed high fat diet, but had no hepatic 
effects in mice fed control diet. 
CD-fed mice did not develop significant steatosis by histology (Oil Red 0 
and H&E stains-Figure 5 & 6) with either vehicle control or PCB 153. In contrast, 
HFD increased steatosis which appeared to be even greater with PCB 153 co-
exposure (vs. vehicle). 
Hepatic necro-inflammation was evaluated by histology (H&E), plasma 
aminotransferase activity, and hepatic TNFa message (RT-PCR). Qualitatively, 
significant necro-inflammation was not observed histologically in either group 
(Figure 6). Mean plasma AST activity levels were slightly, but significantly higher 
with HFD+PCB 153 (54.13 ± 4.65 U/L) vs. either CD+vehicie (37.09 ± 1.99 U/L, P 
<0.05) or CD+PCB 153 (37.68 ± 1.17 U/L, P <0.05) (Figure 7). The mean AST 
level in the HFD+vehicle group (49.85±4.52 U/L) was significantly different vs. 
CD+vehicie group (p <0.05) but not vs. CD+PCB 153. Mean plasma AL T activity 
levels were not significantly different between groups (Figure 8). Hepatic TNFa 
message was measured by RT PCR and normalized to GAPDH. Mean TNFa 
message levels were not significantly different between groups: CD+vehicle (100 
± 24.03); CD+PCB 153 (106.90 ± 40.06); HFD+vehicie (285.57 ± 109.73); 
HFD+PCB 153 (60.47 ± 16.81). Hepatic fibrosis was evaluated by Sirius red 
stain. As no qualitative differences were observed between treatment groups 
(data not shown), quantitative studies were not performed. 
20 
Hepatic triglycerides and cholesterol were quantitated biochemically. In 
CD-fed mice, mean hepatic triglycerides were not significantly different between 
vehicle (7.29 ± 1.20 Ilg/mg tissue) and PCB 153 treatment (4.63 ± 1.85 Ilg/mg 
tissue) (Figure 9). Likewise, hepatic cholesterol levels were not significantly 
different between vehicle (2.75 ± 0.39 Ilg/mg tissue) and PCB 153 (3.15 ± 0.93 
Ilg/mg tissue) treated mice fed with CD (Figure 10). In contrast, HFD-fed mice 
had significantly higher mean hepatic triglyceride levels with PCB 153 (56.37 ± 
14.36 Ilg/mg tissue) VS. vehicle control (17 ± 6.35 Ilg/mg tissue, p <0.05). Indeed, 
HFD+PCB 153 co-exposure resulting in significantly higher hepatic triglycerides 
than all other treatments. Hepatic cholesterol levels were not significantly 
different between HFD+vehicie (5.08 ± 1.49 Ilg/mg tissue) VS. HFD+PCB 153 
(9.26 ± 2.21 Ilg/mg tissue). However, mean hepatic cholesterol levels were 
significantly higher with HFD+PCB 153 VS. both CD+vehicle or CD+PCB 153 
(Figure 10). 
In summary, the combination of PCB 153 and HFD dramatically increased 
steatosis, marginally worsened necro-inflammation, but had no effect on fibrosis. 
PCB 153 had no effect on these parameters in mice fed CD. 
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CD CD+PCB 153 
HFD HFD+PCB153 
Figure 5. Oil Red 0 staining of liver tissue. 
Oil Red 0 staining of hepatic sections establ ished the occurrence of micro-
vesicular steatosis in the HFO+PCB 153 mice. There was no evidence of micro-
vesicular steatosis in mice fed CO without or with PCB 153 co-administration. 
CD-control diet, HFO-high fat diet, PCB-polychlorinated biphenyl. 
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CD CD+PCB153 
HFD HFD+ PCB 153 
Figure 6. H&E staining of liver tissue. 
H&E staining of hepatic sections established the occurrence of macro-vesicular 
steatosis in the HFD+PCB 153 mice. Macro-vesicular steatosis was not observed 
in mice fed CD without or with PCB 153 co-administration. CD-control diet, HFD-








Figure 7. Effects of HFD and PCB 153 on plasma AST levels. 
Plasma AST levels (U/L) were measured (n=10) using Cobas Mira Plus 
automated chemical analyzer. The AST levels were significantly higher for the 
HFD+PCB 153 group as compared to CD or CD+PCB 153. Data are expressed 
as mean ± SEM. * P <0.05. CD-control diet, HFD-high fat diet, PCB-
polychlorinated biphenyl , AST-aspartate transaminase. 
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Figure 8. Effects of HFD and PCB 153 on plasma AL T levels. 
Plasma AL T levels (U/L) were measured (n=10) using Cobas Mira Plus 
automated chemical analyzer. No significant change was observed in any group. 
Data are expressed as mean ± SEM. * P <0.05. CD-control diet, HFD-high fat 
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Figure 9. Effects of HFD and PCB 153 on hepatic triglyceride levels. 
Hepatic levels of triglycerides were quantified (Ilg/mg tissue) in mice (n=5) fed 
with control or high fat diet with or without PCB 153. PCB 153 increased hepatic 
triglyceride levels in mice fed a HFD. Data are expressed as mean ± SEM. * P 
<0.05. CD-control diet, HFD-high fat diet, PCB-polychlorinated biphenyl. 
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Figure 10. Effects of HFD and PCB 153 on hepatic cholesterol levels. 
Hepatic levels of cholesterol were quantified ( ~g/mg tissue) in mice (n=5) fed with 
control or high fat diet with or without PCB 153. PCB 153 increased hepatic 
cholesterol levels in mice fed a HFD. Data are expressed as mean ± SEM. * P 
<0.05. CD-control diet, HFD-high fat diet, PCB-polychlorinated biphenyl. 
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Insulin resistance, glucose regulation and serum lipoproteins: Effects of 
HFD and PCB 153. 
In order to evaluate insulin resistance which may complicate obesity, 
HOMA-IR was determined and GTT was performed. As observed by HOMA-IR 
(Figure 11) HFD+vehicie (3.80 ± 0.48) was associated with insulin resistance but 
this effect was not augmented by HFD+PCB 153 (3.83 ± 0.62). However, HOMA-
IR levels were significantly higher in HFD+vehicle vs. CD+vehicie (1.26 ± 0.17) 
and CD+PCB 153 (1.30 ± 0.35, P <0.05). Likewise, HOMA-IR levels were 
significantly higher in HFD+PCB 153 vs. CD+vehicie and CD+PCB 153 (p 
<0.05). GTT was performed and compared to CD; PCB 153 had no additive 
effect to dietary manipulation alone (Figure 13). However, in CD-fed mice, PCB 
153 administration was associated with lower fasting blood glucose levels 
(170.40 ± 4.57 mg/dL for CD+vehicie vs. 147.10 ± 5.92 mg/dL CD+PCB 153, 
p=0.006) (Figure 12). Furthermore, HFD+vehicie and HFD+PCB 153 significantly 
increased the glucose area under the curve (AUC) (Figure 13 & 14) (p <0.05) 
which was obtained from GTT. 
The plasma levels of total cholesterol, triglycerides, high density 
lipoproteins (HDL) and low density lipoproteins (LDL) were measured in all 
animal groups (Table 2). No significant differences in total cholesterol, 
triglycerides, LDL and HDL were observed in mice administered CD+vehicle vs. 
CD+PCB 153. Likewise mean lipid levels were unchanged in HFD+vehicle vs. 
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HFO+PCB 153. However, total cholesterol, LOL, and HOL were significantly 
higher for HFO+PCB 153 vs. CO+PCB 153 (p <0.05 - Table 2). 
In summary, HFO was associated with insulin resistance and serum 


















Figure 11. HFD increased insulin resistance and this was unaffected by 
PCB 153 co-exposure. 
HOMA-IR was caluclated from fasting blood glucose and insulin levels for all four 
groups of animals (n=10). HFD and HFD+PCB 153 groups showed higher levels 
of HOMA-IR, indicative of insulin resistance, as compared to CD and CD+PCB 
153 groups. Data are expressed as mean ± SEM. * P <0.05. CD-control diet, 
HFD-high fat diet, PCB-polychlorinated biphenyl. 
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Figure 12. Fasting blood glucose levels. 
Fasting blood glucose levels (mg/dL) were measured for all animals. HFD and 
HFD+PCB 153 showed higher fasting blood glucose levels when compared to 
CD group. CD+PCB 153 showed significantly lower fasting blood glucose levels 
when compared to CD alone. Data are expressed as mean ± SEM. * P <0.05. 
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Figure 13. Glucose tolerance test (GTT). 
Glucose tolerance test was performed and blood glucose levels were measured 
for mice (n=10) fed with a control or high fat diet, with or without PCB 153. High 
fat diet increased glucose tolerance and this was unaffected by PCB 153. CD-
control diet, HFD-high fat diet, PCB-polychlorinated biphenyl. 
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Figure 14. Area under the curve calculated from GTT. 
Area under the curve was calculated from the glucose tolerance test readings. 
HFD and HFD+PCB 153 groups showed higher AUC levels than CD or CD+PCB 
153 groups. Data are expressed as mean ± SEM. * P <0.05. CD-control diet, 
HFD-high fat diet, PCB-polychlorinated biphenyl. 
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CD CD+PCB 153 HFD HFD+PCB 153 
136.78 ± 141.52 ± 
Cholesterol 70.01 ± 10.29 69.88 ± 16.50 
37.65a 27.49a 
Triglycerides 33.85 ± 12.95 38.63 ± 19.86 23.39 ± 4.17 34.17 ± 27.11 
111.01 ± 113.80 ± 
HDL 54.73 ± 5.07 58.85 ± 10.92 
31.02a 17.69a 
LDL 14.03 ± 2.39 14.29 ± 4.07 33.74 ± 9.67a 31.25 ± 8.79a 
Table 2. Plasma levels of total cholesterol, triglycerides, high density and 
low density lipoproteins 
ap <0.05 compared with mice fed CD alone or co-administered with PCB 153. 
Values are mean ± SEM (mg/dL). CD-control diet, HFD-high fat diet, PCB-




The most striking result of this study was the synergistic interaction 
between PCB 153 and HFD resulting in dramatically increased obesity. 
Historically, exposures to PCBs, and the related molecule TCDD, have been 
associated with wasting syndrome, although hypercaloric diets were not utilized 
(34,35). Consistent with these historical observations, a decrease in % body 
weight gain was observed in the CD-fed mice administered with PCB 153 VS. 
vehicle control. However, recent epidemiological studies, which did not control for 
diet, revealed an association between serum levels of specific PCB congeners 
and human obesity (12, 13). Likewise, an increase in % body weight gain 
corresponding with qualitatively increased visceral fat was observed in mice with 
PCB 153+HFD co-exposure VS. HFD alone. These seemingly paradoxical 
findings could potentially be explained by (i) the fact that PCB 153 is not an AhR 
agonist as are the PCBs used in most prior rodent studies, (ii) AhR has 
dramatically different activities in rodents and humans (36), and (iii) unlike the 
rodent studies, in the epidemiologic studies, humans are simultaneously being 
exposed to hypercaloric diets. Although we can retrospectively rationalize our 
findings, they were nonetheless unexpected. Therefore, metabolic cages were 
not used and adiposity was not precisely quantitated. We were, however, able to 
quantitate adipocyte size which showed that PCB 153 had no effect on adipocyte 
size over HFD alone. 
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Despite changes in obesity, PCB 153 was not associated with increased 
insulin resistance (HOMA-IR). However some alterations were observed in 
glucose metabolism. There was a non-significant trend towards higher AUC 
levels (glucose tolerance test) with significantly lower fasting blood glucose levels 
in CD-fed mice co-administered with PCB 153 which theoretically could be 
explained by CAR activation (37). Notably, PCB 153 was associated with human 
diabetes in adult NHANES (15), indicating that other factors may have driven 
insulin resistance. A more recent prospective human study determined that 
higher baseline levels of PCBs with greater than 7 chlorine atoms (and not PCB 
153 that has six chlorines) were associated with the subsequent development of 
greater BMI, insulin resistance, and triglycerides (38). Therefore, it appears that 
the effects of PCBs on obesity/metabolic syndrome may be congener-dependent 
and depend on affinity for the AhR and degree of chlorination. 
Concordant with the increase in obesity, PCB 153 worsened NAFLD in 
HFD mice. Steatosis was dramatically increased by the combination of PCB 
153+HFD. In contrast to steatosis, which increased considerably, hepatic necro-
inflammation was only minimally increased by HFD+PCB 153. While mean 
plasma AST activity was significantly increased in this group, no significant 
changes were observed in ALT, necro-inflammation by histology, hepatic TNFa 
message levels, or plasma levels of TNFa, IL-6, or IL-10. Previous 
epidemiological study from our laboratory found a dose-dependent association 
between plasma PCB levels and elevated ALT in adult NHANES subjects (4). 
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However, weaker associations were also noted between PCBs and elevated AST 
levels. PCB 153 was not associated with hepatic inflammation, although 
preliminary in vitro studies from our laboratory showed that PCB exposures 
increased TNFa production from Raw 264.7 cells, a murine macrophage cell line 
(39). However, these differences could be PCB congener/dose specific or related 
to differences between in vitro vs. in vivo systems. 
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CHAPTER 3 
MECHANISMS BY WHICH PCB 153 PROMOTE OBESITY 
INTRODUCTION 
The characteristics of NAFLD/obesity include but are not limited to hepatic 
steatosis, insulin resistance and increased serum cholesterol. Adipokine 
dysregulation is another probable factor that drives NAFLD towards metabolic 
syndrome. Furthermore, in our studies, there was marked evidence for the 
occurrence of hepatic steatosis in mice fed a HFD and co-exposed to PCB 153. 
Deposition of fat in the liver can occur through different mechanisms such as 
increased synthesis and decreased catabolism of fat in liver (40) or increased 
import of fat to liver and decreased export to other tissues (24). We therefore 
measured the serum levels of adipokines such as adiponectin, leptin, resistin and 
tissue plasminogen activator inhibitor (t-PAI 1) as well as cytokines. 
To further understand the mechanism that led to steatosis, mRNA 
expression of enzymes involved in fatty acid metabolism was examined. These 
enzymes included fatty acid synthase (FAS) for fatty acid synthesis, PPARa and 
carnitine palmitoyl transferase 1A and 2 (CPT1A and 2) for fatty acid oxidation. 
The mRNA expression of fatty acid binding protein 1 (FABP1), utilized for fatty 
acid transport, was also examined. 
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Another aspect that we studied is related to the slight increase in 
adiponectin levels in the plasma as compared to the high fold-change observed 
with leptin in the HFD+PCS 153 group. We hypothesize that the decreased 
adiponectin:leptin ratio seen in this group may be due to endoplasmic reticulum 
(ER) stress brought upon by PCS exposure in high fat-fed mice. 
ER stress refers to the phenomenon when the protein load in the ER 
exceeds the ER folding capacity; hence, also known as unfolded protein 
response (UPR) (41). Synthesis, folding and maturation of secreted and 
transmembrane proteins occur in the endoplasmic reticulum (ER). ER is also the 
site of lipid biosynthesis and calcium (Ca2+) storage. Causes of ER stress are 
diverse and range from Ca2+ to cholesterol accumulation and phospholipid 
depletion (42). 
One of the defining features in ER stress is the upregulation of the CAAT-
enhancer binding protein (C/ESP) homologous protein 10 (CHOP 10), also 
known as DNA damage-inducible transcript 3 (DOlT 3) (43). CHOP-10 belongs to 
the family of bliP C/ESP like transcription factors and has been implicated in ER 
stress, oxidative stress and nutrient deprivation (44, 45). UPR is an adaptive 
mechanism initiated by the cell in response to demand for protein folding. The 
presence of misfolded proteins in ER attracts immunoglobulin heavy chain 
binding protein (SiP); SiP's principal role is to bind to ER stress transducers in 
their inactive form towards it (41). Dissociation of the chaperone protein SiP from 
the ER stress transducer protein kinase RNA-activated (PKR)-like ER kinase 
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(PERK) leads to phosphorylation of the translation initiation factor 2 (eIF2a) 
(Figure 15). Phosphorylation of elF2a leads to nuclear translocation of activating 
nuclear transcription 4 (ATF4) which induces CHOP 10 (46, 47). CHOP 10 plays 














Figure 15. Upregulation of CHOP 10 in endoplasmic reticulum (ER) stress. 
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Growth and differentiation of preadipocytes involve a complex sequence 
of transcription factors that are interdependent and can either stimulate or inhibit 
adipocyte differentiation, eventually affecting adipocyte genes and adipocyte 
secretory hormone levels. 
Adipocytes or fat cells arise from fibroblasts that require growth arrest and 
terminal differentiation to become functional and matured adipocytes. Growth 
arrest is controlled by CAAT -enhancer binding protein alpha (C/EBPa) and 
peroxisome proliferator-activated receptor gamma (PPARy), transcription factors 
that transactivate adipocyte-specific genes (48). C/EBPa increases p21 (cyclin-
dependent kinase inhibitor) levels and has anti-mitotic activity (50) while PPARy 
decreases the transcriptional activity of E2F/DP-1 complex which controls DNA 
synthesis (51). PPARy attains maximal level of expression in matured 
adipocytes. C/EBPI3, a transcriptional activator of C/EBPa and C/EBPo, 
precedes C/EBPa expression. CHOP 10 is expressed in growth arrested 
preadipocytes and it transiently sequesters C/EBPI3 by heterodimerization (52). 
C/EBPI3 and C/EBPo co-expression is essential for PPARy expression (53), thus 
these transcription factors have temporal and spatial expressions that influence 
each other. Therefore, CHOP 10 is a negative modulator of the C/EBP 
transcriptional activity and its upregulation leads to decreased C/EBPI3 and 
C/EBPo levels, which subsequently repress C/EBPa and PPARy expression. 
Suggested PPARy target genes include adiponectin, lipoprotein lipase (LPL) and 
adipocyte protein 2 (aP2) or fatty acid binding protein 4 (FABP4) (54, 55). 
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MATERIALS AND METHODS 
Cytokines and adipokines measurement. Plasma cytokine and adipokine 
levels were measured using Milliplex Mouse Serum Cytokine and Adipokine Kits 
(Millipore Corp, Billerica, MA) on the Luminex IS 100 system (Luminex Corp, 
Austin, TX), as per the manufacturer's instructions. 
Real time-PCR. Mouse liver and adipose tissue samples were homogenized and 
total RNA was extracted using the RNA-STAT 60 protocol (Tel-Test, Austin, TX). 
cDNA was synthesized from total RNA using the QuantiTect Reverse 
Transcription Kit (Qiagen, Valencia, CA). PCR was performed on the Applied 
Biosystems StepOnePlus Real-Time PCR Systems using the Taqman Universal 
PCR Master Mix (Life Technologies, Carlsbad, CA). Primer sequences (Taqman 
Gene Expression Assays) were obtained from Applied Biosystems (Foster City, 
CA) and included the following (with the catalogue number): fatty acid synthase 
(FAS) (Mm00662319-m 1), peroxisome proliferator-activated receptor alpha 
(PPARa) (Mm00440939-m1), carnitine palmitoyltransferase 1A (CPT1A) 
(Mm01231183-m1), carnitine palmitoyltransferase 2 (CPT2) (Mm00487205-m1), 
fatty acid binding protein 1 in liver (FABP1) (Mm00444340-m1), peroxisome 
proliferator-activated receptor gamma (PPARy) (Mm01184322-m1), CCAAT-
enhancer-binding protein alpha (C/EBPa) (Mm00514283-s1), C/EBP 
homologous protein (CHOP 10) (Mm00492097 -m 1) and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (4352932E). The levels of mRNA were 
normalized relative to the amount of GAPDH mRNA, and expression levels in 
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mice fed CD and administered vehicle were set at 100%. Gene expression levels 
were calculated according to the 2-MCt method (33). 
Statistical Analysis. Statistical analyses were performed using GraphPad Prism 
version 5.01 for Windows and SigmaPlot 11.01. Data are expressed as mean ± 
SEM. For 2 group comparison, an unpaired t-test was used, and multiple group 
data were compared using Two Way ANOVA followed by Tukey Test for post-
hoc all pairwise comparisons. P <0.05 was considered statistically significant. 
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RESULTS 
PCB 153 altered plasma adipokine levels and expression although cytokine 
levels were unchanged. 
HFD+PCB 153 increased leptin levels 56-fold VS. CD+vehcile (p <0.05); 
and 25-fold VS. CD+PCB 153 (p <0.05) (Table 3). Three additional adipokines, 
adiponectin, resistin and tPAI-1, were also determined (Table 3). Compared to 
the large magnitude changes observed in plasma leptin levels, adiponectin levels 
were changed by a smaller amount. Adiponectin levels were higher in 
HFD+vehicie VS. CD+vehicie and CD+PCB 153. Likewise, adiponectin levels 
were higher in HFD+PCB 153 VS. both CD and CD+PCB 153. Resistin levels 
were significantly increased in HFD+PCB 153 VS. both HFD+vehicle and 
CD+vehicie (p <0.05). Resistin levels were also significantly higher in 
HFD+vehicie VS. CD+vehicie (p <0.05). No differences were noted between 
CD+PCB 153 VS. any other group. Similarly, mean plasma tPAI-1was 
significantly increased in HFD+PCB 153 VS. HFD+vehicie and VS. CD+vehicie (p 
<0.05). tPAI-1 levels were also significantly higher in HFD+vehicle VS. 
CD+vehicle (p <0.05). Plasma cytokines were measured and no change was 
observed in any of the animal groups for the pro-inflammatory cytokines, TNFa 
and IL-6, and the anti-inflammatory cytokine IL-10 (Table 3). Therefore, 
HFD+PCB 153 co-exposures led to significant changes in adipokines including 
the adiponectin, leptin, resistin, and tPAI-1; but did not affect cytokines including 
TNFa, IL-6, or IL-10. 
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Adipocytokines CD CD+PCB 153 HFD HFD+PCB 153 
Adiponectin 
6.39 ± 0.30 6.57 ± 0.38 9.01 ± 0.87a 11.33 ± 1.11 a 
(J.lg/mL) 
116.67± 1279.28 ± 6543.00 ± 
Leptin (pg/mL) 254.87 ± 55.46 
39.93 360.11 a 3550.89a 
742.02 ± 941.09 ± 1359.99 ± 
Resistin (ngl mL) 838.02 ± 246.11 
134.44 310.87a 325.47a,b 
152.47± 363.80 ± 533.39 ± 
tPAI-1 (ng/mL) 218.05 ± 91.06 
71.32 142.82a 207.82a,b 
TNFa (pg/mL) 0.52 ± 0.49 0.65 ± 0.70 0.99 ± 1.44 0.58 ± 0.88 
IL-6 (pg/mL) 3.80 ± 2.62 5.31 ± 5.79 12.69 ± 13.07 6.65 ± 8.12 
IL-10 (pg/mL) 1.54 ± 0.33 1.42 ± 0.27 3.55 ± 3.03 2.68 ± 2.90 
Table 3. Plasma cytokines' and adipokines' levels 
ap <0.05 compared with mice fed CD alone or co-administered with PCB 153. b 
p<0.05 compared with mice fed HFD alone. Values are mean ± SEM. CD-control 
diet, HFD-high fat diet, PCB-polychlorinated biphenyl, tPAI-1-tissue plasminogen 
activator inhibitor 1, TNFa-tumor necrosis factor alpha, IL-interleukin. 
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PCB 153 exposure altered gene expression of enzymes involved in hepatic 
lipid metabolism. 
Real-time PCR was performed with total liver mRNA to analyze potential 
changes in expression of selected genes involved in fatty acid metabolism: FAS, 
PPARa, and CPT1A12. 
FAS expression was significantly increased in HFD+PCB 153 (2530.53 ± 
1436.48) VS. CD+vehicie (100 ± 39.30, P <0.05) and VS. CD+PCB 153 (422.05 ± 
169.58, p <0.05) (Figure 16). Lower FAS expression was observed in 
HFD+vehicie (472.78 ± 382.25) VS. HFD+PCB 153, and this was statistically 
significant (p <0.05). Interestingly, HFD+vehicie showed significantly higher FAS 
expression when compared to CD+vehicie group. 
PPARa expression was significantly decreased in HFD+PCB 153 (19.09 ± 
7.89) VS. CD+PCB 153 (112.64 ± 35.08, P <0.05) and VS. CD+vehicie (100 ± 
19.51, P <0.05) (Figure 17). No significant differences were seen in PPARa 
expression in HFD+vehicie (40.98 ± 13.17) VS. any other group; although there 
was a non-significant trend towards higher PPARa VS. HFD+PCB 153. CPT1A, a 
PPARa target gene and the rate limiting step in hepatic ~ oxidation, was 
decreased in HFD+PCB 153 (13.83 ± 6.85) VS. CD+vehicle (100 ± 22.63, P 
<0.05) (Figure 18). Mean CPT2 expression was significantly decreased in 
HFD+PCB 153 (14.58 ± 5.53) VS. CD+vehicle (100 ± 15.15, P <0.05); and also in 
HFD+vehicie (49.72 ± 29.45) VS. CD+vehicle (p <0.05) (Figure 19). CPT2 
expression was numerically lower in HFD+PCB 153 than HFD+vehicle, but this 
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observed trend was not statistically significant. FABP1 gene expression did not 
differ significantly between PCB-exposed and unexposed groups fed either a 
control or HFD. 
Therefore, with HFD+PCB 153 co-exposure, the overall picture favored 
increased expression of genes implicated in fatty acid synthesis and decreased 











Figure 16. HFD and PCB exposure altered expression of FAS in liver. 
Real-time PCR experiments showed the changes in hepatic mRNA expressions 
for fatty acid synthase (FAS) in mice liver caused by either PCB 153 exposure or 
HFD consumption or both as compared to gene expression in mice fed CD 
without or with PCB 153 exposure. All values were normalized to CD group, 
(n=10). Data are expressed as mean ± SEM. * P <0.05. CD-control diet, HFD-








Figure 17. HFD and PCB exposure altered expression of PPARa in liver. 
Real-time PCR experiments showed the changes in hepatic mRNA expressions 
for peroxisome proliferation activator alpha (PPARa) in mice liver caused by 
either PCB 153 exposure or HFD consumption or both as compared to gene 
expression in mice fed CD without or with PCB 153 exposure. All values were 
normalized to CD group, (n=10). Data are expressed as mean ± SEM. * P <0.05. 










Figure 18. HFD and PCB exposure altered expression of CPT1 A in liver. 
Real-time PCR experiments showed the changes in hepatic mRNA expressions 
for carnitine palmitoyl transferase 1 A (CPT1 A) in mice liver caused by either PCB 
153 exposure or HFD consumption or both as compared to gene expression in 
mice fed CD without or with PCB 153 exposure. All values were normalized to 
CD group, (n=10). Data are expressed as mean ± SEM. * P <0.05. CD-control 












Figure 19. HFD and PCB exposure altered expression of CPT2 in liver. 
Real-time PCR experiments showed the changes in hepatic mRNA expressions 
for carn itine palmitoyl transferase 2 (CPT2) in mice liver caused by either PCB 
153 exposure or HFD consumption or both as compared to gene expression in 
mice fed CD without or with PCB 153 exposure. All values were normalized to 
CD group, (n=10). Data are expressed as mean ± SEM. * P <0.05. CD-control 
diet, HFD-high fat diet, PCB-polychlorinated biphenyl. 
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The role of PCB 153 in endoplasmic reticulum stress. 
Our RT -PCR studies on the adipose tissue of C57BI/6 mice fed either CD 
or HFD with or without PCB 153 co-administration showed interesting results that 
suggested the role of PCBs as ER stress inducers in the presence of HFD. RT-
PCR was performed on mRNA extracted from the mouse adipose tissue for 
adiponectin, CHOP 10, C/EBPa and PPARy. 
Adiponectin mRNA levels decreased significantly in the HFD+PCB 153 
group (2.77 ± 1.06) and HFD+vehicie group (24.90 ± 16.92) when compared to 
CD+vehicle (100 ± 23.66, P <0.05) (Figure 20). CHOP 10 mRNA expression 
increased significantly in the HFD+vehicie (610.89 ± 194.73) and HFD+PCB 153 
group (325.66 ± 139.06) vs. CD+vehicie (100 ± 37.30, P <0.05) (Figure 21). 
C/EBPa showed a trend towards lower mRNA expression in HFD+vehicie and 
HFD+PCB 153 groups when compared to CD+vehicle or CD+PCB 153 groups 
(Figure 22) . PPARy mRNA expression (Figure 23) decreased significantly for the 
HFD+PCB 153 group (11.42 ± 2.43) as compared to CD+vehicie group (100 ± 
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Figure 20. HFD and PCB exposure altered expression of adiponectin in 
adipose tissue. 
Real-time PCR experiments showed the changes in adiponectin mRNA 
expression in the adipose tissue caused by either PCB 153 exposure or HFD 
consumption or both as compared to gene expression in mice fed CD without or 
with PCB 153 exposure. All values were normalized to CD group, (n=5). Data are 














Figure 21. HFD and PCB exposure altered expression of CHOP 10 in 
adipose tissue. 
Real-time PCR experiments showed the changes in CHOP 10 mRNA expression 
in the adipose tissue caused by either PCB 153 exposure or HFD consumption 
or both as compared to gene expression in mice fed CD without or with PCB 153 
exposure. All values were normalized to CD group, (n=6). Data are expressed as 











Figure 22. HFD and PCB exposure altered expression of C/EBPa in adipose 
tissue. 
Real-time PCR experiments showed the changes in C/EBPa mRNA expression 
in the adipose tissue caused by either PCB 153 exposure or HFD consumption 
or both as compared to gene expression in mice fed CD without or with PCB 153 
exposure. All values were normalized to CD group, (n=4). Data are expressed as 







Figure 23. HFD and PCB exposure altered expression of PPARy in adipose 
tissue. 
Real-time PCR experiments showed the changes in PPARy mRNA expression in 
the adipose tissue caused by either PCB 153 exposure or HFD consumption or 
both as compared to gene expression in mice fed CD without or with PCB 153 
exposure. All values were normalized to CD group, (n=7). Data are expressed as 




PCBs are known to concentrate within adipose tissue and liver, so it is not 
surprising that these were the principal target sites for PCB 153 toxicity in this 
study. Although PCB 153 levels were not measured, we expect them to be 
similar to those in the NTP TR 530 14-week study (16). The NTP protocol 
resulted in the following PCB 153 levels: lipid adjusted serum-1788 ng/g; liver-
34,010 ng/g; and adipose-1 ,118,300 ng/g. Thus, PCB 153 accumulates in the 
adipose tissue and is likely to exert its effects at this site. 
In our results, PCB 153 exposure to the HFD group altered multiple 
adipokines including leptin, tPAI-1, resistin and adiponectin. Adiponectin, also 
referred to as GBP-28, apM1, AdipoQ or Acrp30, is an adipocyte-derived 
protein hormone which is encoded by the AD/POQ gene in humans (56). 
Adiponectin regulates glucose and fatty acid catabolism (57) and its plasma 
levels in adults are inversely proportional to body fat percentage (58). Literature 
reports have demonstrated adiponectin's role in suppressing metabolic 
derangements that can occur due to obesity (55), type 2 diabetes mellitus (58), 
atherosclerosis (57) and metabolic syndrome (59). Interestingly, the plasma 
levels of leptin were increased to a greater extent in the HFD+PCB 153 group as 
compared to adiponectin. Leptin, a 30 kDa protein hormone encoded by the 
Ob(Lep) gene, is also secreted by the adipocytes and plays a crucial role in 
modulating energy intake and expenditure as well as appetite suppression (60, 
61). Circulating levels of leptin are directly correlated with body fat mass and 
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adipocyte size, with increasingly high levels seen in obesity (62). The overall 
increase in adiposity in the HFO+PCB 153 animals may be responsible for the 
increased circulating levels of leptin. Our results indicated that the observed 
disproportion of adiponectin to leptin increment in the plasma of animals treated 
with HFO+PCB 153 was due to increased adiposity and probably increased leptin 
/decreased adiponectin production in the adipose tissue. 
Steatosis was dramatically increased by the combination of PCB 
153+HFO, whereas PCB 153 had no effect in mice fed CD. Steatosis is 
determined by the rates of lipid synthesis, oxidation, uptake, and export. The RT-
PCR results suggest that PCB 153+HFO co-exposures increased hepatic lipid 
synthesis (up-regulated FAS) while decreasing ~-oxidation (down-regulated 
CPT1A and CPT2 and its transcription factor, PPARa). Therefore, PCB 153 
seemed likely to increase hepatic steatosis in mice fed HFO by altering 
adipokines, increasing hepatic lipid synthesis, and decreasing hepatic ~­
oxidation. This hypothesis will be investigated further in future studies. 
RT-PCR results showed a marked decrease in adiponectin expression 
levels in the adipose tissue. Interestingly, adiponectin plasma levels were 
increased in this group. This can be explained by increased fat mass in these 
animals that led to overall higher adiponectin secretion while the adiponectin 
synthesis per fat cell was decreased. The resulting adiponectin mRNA 
expression observed in the adipose tissue led us to hypothesize that PCB 153 
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may act as an ER stress inducer in the adipose tissue in the presence of HFD. 
We therefore looked at the mRNA expression of proteins that playa major role in 
ER stress response, namely, CHOP 10 which is upregulated in ER stress, 
C/EBPa, required for adipocyte differentiation and negatively regulated by CHOP 
10, and PPARy, a positive transcription factor for adiponectin. Indeed, mRNA 
expression was increased for CHOP 10 and repressed for CEBPa. PPARy 
mRNA expression was also reduced in PCB 153-exposed mice fed with HFD. 
In general, HFD consumption and PCB 153 co-exposure led to increased 
lipogenesis in the liver by upregulation of FAS, and a decrease in PPARa 
mediated fatty acid-~-oxidation. Furthermore, there is evidence of adipokine 
dysregulation in the HFD+PCB 153 group. These finding s are important because 
they implicate PCB 153 exposure in hepatic steatosis and adipokine 
dysregulation, hallmarks of the metabolic syndrome. The presence of an ER 
stress response is also speculated in the adipose tissue due to low adiponectin 
secretion. However, this study requires further investigation. 
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SUMMARY 
PCBs are poly-halogenated hydrocarbons which are persistent 
contaminants in our environment. Exposure to PCBs including the ubiquitous 
PCB 153 has been dose dependently linked to increased odds ratio for serum 
alanine aminotransferase elevation, indicative of NAFLD. To determine if 
PCB153 plays a casual role in the development of NAFLD, a study was 
undertaken to determine if PCB 153 either caused NALFD by itself or worsened 
NAFLD induced by HFD consumption. 
It was observed that PCB153 exposure caused an increase in % body 
weight for animals fed a HFD. PCB 153 exposure also caused micro-vesicular 
steatosis in animals fed a HFD and worsened HFD-induced macro-vesicular 
steatosis. Serum adipokines were increased with HFD and this effect was 
augmented by PCB 153 co-administration. PCB 153 treatment increased liver 
triglycerides and cholesterol levels in the HFD group of animals. FAS expression 
was upregulated and PPARa expression downregulated in the liver of animals 
fed a HFD and co-exposed to PCB 153. The adiponectin mRNA level decreased 
in the HFD+PCB153 group. 
61 
In conclusion, PCB 153 is a diet-dependent obesogen, which also 
worsens NAFLD via adipokine dysregulation and altered lipid metabolism. These 
experimental results suggest that the previously observed associations between 
PCB levels and human obesity/NAFLD may be causal. Nutrient-toxicant 
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